Perrigo Company plc (PRGO)

NYSE - Nasdaq Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

41.87

+0.22

(+0.53%)

At close: 04:00PM EDT

41.87

0.00

(0.00%)

After hours:

04:30PM EDT

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Price Crosses Moving Average

View all chart patterns

Performance Outlook

Previous Close	41.65
Open	41.95
Bid	41.88 x 1300
Ask	41.89 x 800
Day's Range	41.40 - 42.09
52 Week Range	31.32 - 50.90
Volume	885,471
Avg. Volume	1,348,708

Market Cap	5.636B
Beta (5Y Monthly)	0.91
PE Ratio (TTM)	N/A
EPS (TTM)	-0.82
Earnings Date	Aug 09, 2022
Forward Dividend & Yield	1.04 (2.49%)
Ex-Dividend Date	Sep 01, 2022
1y Target Est	N/A

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

-61% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for PRGO

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Perrigo Company plc
Analyst Report: Perrigo Company plcPerrigo is a leading private label supplier of generic over the counter (OTC) drugs in the U.S. and Europe. The company’s product offerings fall under traditional OTC drug categories (i.e. cough, cold, allergy, pain), in addition to oral care, infant nutrition (formula), and nicotine cessation aids. In addition to private label manufacturing, the company also sells products under its own brands (largely in the skincare and oral-care category). The company became a pure-play in OTC consumer healthcare in 2021, following a series of divestures over several years (sold off generic prescription topicals, animal health, and active pharmaceutical ingredient business). In late 2021, Perrigo signed an offer to acquire HRA Pharma.
Rating
Fair Value
Economic Moat
2 months agoMorningstar